BC is highly heterogeneous, and treatment strategies vary according to the molecular characteristics, including human epidermal growth factor receptor 2 (HER2) activation, expression of hormone receptors, gene mutations, and immune microenvironment markers (2). Here, ERBB2 is linked to breast cancer.